questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Transferases
One-carbon group transferases
Methyltransferases
Protein Methyltransferases
Histone méthyltransférases
Histone méthyltransférases : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Méthyltransférases
Analyse génétique
Marqueurs biologiques
Méthylation des histones
Biopsie
Méthylation des histones
Tests enzymatiques
Chromatine
Imagerie moléculaire
Chromatine
Symptômes
5
Troubles du développement
Cancers
Troubles neurologiques
Méthyltransférases
Maladies auto-immunes
Méthyltransférases
Types de méthyltransférases
Symptômes
Prévention
5
Prévention
Mode de vie sain
Facteurs environnementaux
Toxines
Alimentation
Régulation épigénétique
Suppléments
Santé épigénétique
Éducation à la santé
Facteurs de risque
Traitements
5
Inhibiteurs
Méthyltransférases
Thérapie génique
Méthyltransférases
Médecine personnalisée
Profil génétique
Essais cliniques
Traitements
Cancer
Efficacité des traitements
Complications
5
Réversibilité
Gestion des complications
Maladies chroniques
Anomalies
Qualité de vie
Complications
Âge
Exposition cumulative
Facteurs de risque
5
Facteurs de risque
Prédispositions génétiques
Stress
Régulation épigénétique
Habitudes de vie
Anomalies épigénétiques
Antécédents familiaux
Risque accru
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Histone méthyltransférases : Questions médicales les plus fréquentes",
"headline": "Histone méthyltransférases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Histone méthyltransférases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-28",
"dateModified": "2025-04-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Histone méthyltransférases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protein Methyltransferases",
"url": "https://questionsmedicales.fr/mesh/D011496",
"about": {
"@type": "MedicalCondition",
"name": "Protein Methyltransferases",
"code": {
"@type": "MedicalCode",
"code": "D011496",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.555.500.800"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Histone-lysine N-methyltransferase",
"alternateName": "Histone-Lysine N-Methyltransferase",
"url": "https://questionsmedicales.fr/mesh/D011495",
"about": {
"@type": "MedicalCondition",
"name": "Histone-lysine N-methyltransferase",
"code": {
"@type": "MedicalCode",
"code": "D011495",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.555.500.800.200.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Histone méthyltransférases",
"alternateName": "Histone Methyltransferases",
"code": {
"@type": "MedicalCode",
"code": "D000076983",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Abbas H K Al Temimi",
"url": "https://questionsmedicales.fr/author/Abbas%20H%20K%20Al%20Temimi",
"affiliation": {
"@type": "Organization",
"name": "Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ, Nijmegen, The Netherlands."
}
},
{
"@type": "Person",
"name": "Jasmin Mecinović",
"url": "https://questionsmedicales.fr/author/Jasmin%20Mecinovi%C4%87",
"affiliation": {
"@type": "Organization",
"name": "Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ, Nijmegen, The Netherlands."
}
},
{
"@type": "Person",
"name": "Danny C Lenstra",
"url": "https://questionsmedicales.fr/author/Danny%20C%20Lenstra",
"affiliation": {
"@type": "Organization",
"name": "Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ, Nijmegen, The Netherlands."
}
},
{
"@type": "Person",
"name": "Ping Qian",
"url": "https://questionsmedicales.fr/author/Ping%20Qian",
"affiliation": {
"@type": "Organization",
"name": "Chemistry and Material Science Faculty, Shandong Agricultural University, Daizong Road No.61, Tai'an, 271018, P.R. China."
}
},
{
"@type": "Person",
"name": "Hong Guo",
"url": "https://questionsmedicales.fr/author/Hong%20Guo",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, 1311 Cumberland Avenue, Knoxville, TN, 37996, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Communication Overload in Hospitals: Exploring Organizational Safety Communication, Worker Job Attitudes, and Communication Efficacy.",
"datePublished": "2022-09-29",
"url": "https://questionsmedicales.fr/article/36172847",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/10410236.2022.2129313"
}
},
{
"@type": "ScholarlyArticle",
"name": "Strategic communication as planned behavior for science and risk communication: A theory-based approach to studying communicator choice.",
"datePublished": "2022-09-18",
"url": "https://questionsmedicales.fr/article/36116781",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/risa.14029"
}
},
{
"@type": "ScholarlyArticle",
"name": "Communication Openings: A Novel Approach for Serious Illness Communication in Homecare.",
"datePublished": "2023-11-01",
"url": "https://questionsmedicales.fr/article/37906048",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3928/00989134-20231011-02"
}
},
{
"@type": "ScholarlyArticle",
"name": "Everyday Barriers in Communicative Participation According to People With Communication Problems.",
"datePublished": "2023-02-14",
"url": "https://questionsmedicales.fr/article/36787154",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1044/2022_JSLHR-22-00405"
}
},
{
"@type": "ScholarlyArticle",
"name": "Beyond dyadic communication: Network of communication in inflammatory arthritis teams.",
"datePublished": "2022-05-29",
"url": "https://questionsmedicales.fr/article/35635126",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/17423953221102629"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Transferases",
"item": "https://questionsmedicales.fr/mesh/D014166"
},
{
"@type": "ListItem",
"position": 5,
"name": "One-carbon group transferases",
"item": "https://questionsmedicales.fr/mesh/D019875"
},
{
"@type": "ListItem",
"position": 6,
"name": "Methyltransferases",
"item": "https://questionsmedicales.fr/mesh/D008780"
},
{
"@type": "ListItem",
"position": 7,
"name": "Protein Methyltransferases",
"item": "https://questionsmedicales.fr/mesh/D011496"
},
{
"@type": "ListItem",
"position": 8,
"name": "Histone méthyltransférases",
"item": "https://questionsmedicales.fr/mesh/D000076983"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Histone méthyltransférases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Histone méthyltransférases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Histone méthyltransférases",
"description": "Comment diagnostiquer une dysfonction des histone méthyltransférases ?\nQuels marqueurs biologiques sont associés aux histone méthyltransférases ?\nLes biopsies peuvent-elles aider au diagnostic ?\nQuels tests sont utilisés pour évaluer l'activité des méthyltransférases ?\nPeut-on utiliser l'imagerie pour diagnostiquer des anomalies ?",
"url": "https://questionsmedicales.fr/mesh/D000076983?mesh_terms=Communication#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Histone méthyltransférases",
"description": "Quels symptômes sont liés aux anomalies des histone méthyltransférases ?\nLes troubles neurologiques sont-ils associés à ces enzymes ?\nY a-t-il des symptômes spécifiques à surveiller ?\nLes maladies auto-immunes sont-elles liées aux histone méthyltransférases ?\nLes symptômes varient-ils selon le type de méthyltransférase ?",
"url": "https://questionsmedicales.fr/mesh/D000076983?mesh_terms=Communication#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Histone méthyltransférases",
"description": "Peut-on prévenir les anomalies des histone méthyltransférases ?\nY a-t-il des facteurs environnementaux à éviter ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLes suppléments peuvent-ils aider à prévenir des anomalies ?\nL'éducation sur la santé est-elle importante ?",
"url": "https://questionsmedicales.fr/mesh/D000076983?mesh_terms=Communication#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Histone méthyltransférases",
"description": "Quels traitements ciblent les histone méthyltransférases ?\nLa thérapie génique peut-elle être une option ?\nLes traitements sont-ils personnalisés selon le patient ?\nY a-t-il des essais cliniques en cours ?\nLes traitements sont-ils efficaces contre le cancer ?",
"url": "https://questionsmedicales.fr/mesh/D000076983?mesh_terms=Communication#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Histone méthyltransférases",
"description": "Quelles complications peuvent survenir avec des anomalies des méthyltransférases ?\nLes complications sont-elles réversibles ?\nY a-t-il un risque accru de maladies chroniques ?\nLes complications affectent-elles la qualité de vie ?\nLes complications sont-elles liées à l'âge ?",
"url": "https://questionsmedicales.fr/mesh/D000076983?mesh_terms=Communication#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Histone méthyltransférases",
"description": "Quels sont les principaux facteurs de risque associés ?\nLe stress peut-il influencer l'activité des méthyltransférases ?\nL'âge est-il un facteur de risque ?\nLes habitudes de vie influencent-elles les risques ?\nY a-t-il des antécédents familiaux à considérer ?",
"url": "https://questionsmedicales.fr/mesh/D000076983?mesh_terms=Communication#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des histone méthyltransférases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de l'expression des gènes peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques sont associés aux histone méthyltransférases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux de méthylation des histones peuvent servir de marqueurs biologiques."
}
},
{
"@type": "Question",
"name": "Les biopsies peuvent-elles aider au diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les biopsies tissulaires peuvent révéler des modifications de méthylation."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des méthyltransférases ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des analyses de chromatine sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour diagnostiquer des anomalies ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie moléculaire peut aider à visualiser des anomalies dans la chromatine."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés aux anomalies des histone méthyltransférases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure des troubles du développement et des cancers."
}
},
{
"@type": "Question",
"name": "Les troubles neurologiques sont-ils associés à ces enzymes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies peuvent contribuer à des troubles neurologiques variés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques à surveiller ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des changements dans le comportement et la cognition peuvent être observés."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes sont-elles liées aux histone méthyltransférases ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent un lien entre ces enzymes et les maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de méthyltransférase ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, différents types d'histone méthyltransférases peuvent entraîner des symptômes variés."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies des histone méthyltransférases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un mode de vie sain peut réduire les risques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux à éviter ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des toxines peut influencer l'activité des méthyltransférases."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en nutriments peut soutenir la régulation épigénétique."
}
},
{
"@type": "Question",
"name": "Les suppléments peuvent-ils aider à prévenir des anomalies ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains suppléments, comme les vitamines, peuvent soutenir la santé épigénétique."
}
},
{
"@type": "Question",
"name": "L'éducation sur la santé est-elle importante ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, sensibiliser sur les facteurs de risque peut aider à prévenir des anomalies."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les histone méthyltransférases ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs spécifiques des méthyltransférases sont en développement."
}
},
{
"@type": "Question",
"name": "La thérapie génique peut-elle être une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie génique pourrait corriger des anomalies liées aux méthyltransférases."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés selon le patient ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction du profil génétique du patient."
}
},
{
"@type": "Question",
"name": "Y a-t-il des essais cliniques en cours ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, plusieurs essais cliniques évaluent de nouveaux traitements ciblant ces enzymes."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces contre le cancer ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains traitements montrent des promesses dans la lutte contre les cancers liés aux méthyltransférases."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des anomalies des méthyltransférases ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des cancers, des troubles métaboliques et neurologiques."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de maladies chroniques ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies peuvent augmenter le risque de maladies chroniques variées."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement impacter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles liées à l'âge ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être plus fréquentes avec l'âge et l'exposition cumulative."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque associés ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des prédispositions génétiques et des expositions environnementales."
}
},
{
"@type": "Question",
"name": "Le stress peut-il influencer l'activité des méthyltransférases ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut affecter la régulation épigénétique et l'activité des méthyltransférases."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vieillissement peut affecter l'expression des méthyltransférases."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles les risques ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes de vie malsaines peuvent augmenter le risque d'anomalies épigénétiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des antécédents familiaux à considérer ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies peuvent indiquer un risque accru."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 23/04/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ, Nijmegen, The Netherlands.
Publications dans "Histone méthyltransférases" :
3 publications dans cette catégorie
Affiliations :
Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ, Nijmegen, The Netherlands.
Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, 5230, Odense, Denmark.
Publications dans "Histone méthyltransférases" :
2 publications dans cette catégorie
Affiliations :
Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ, Nijmegen, The Netherlands.
Publications dans "Histone méthyltransférases" :
2 publications dans cette catégorie
Affiliations :
Chemistry and Material Science Faculty, Shandong Agricultural University, Daizong Road No.61, Tai'an, 271018, P.R. China.
Publications dans "Histone méthyltransférases" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, 1311 Cumberland Avenue, Knoxville, TN, 37996, USA.
UT/ORNL Center for Molecular Biophysics, Oak Ridge National Laboratory, 1 Bethel Valley Road, Oak Ridge, TN, 37830, USA.
Publications dans "Histone méthyltransférases" :
2 publications dans cette catégorie
Affiliations :
Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Program in Chemical Biology, University of Michigan, Ann Arbor, MI, USA.
Publications dans "Histone méthyltransférases" :
2 publications dans cette catégorie
Affiliations :
Department of Pathology, University of Michigan, Ann Arbor, MI, USA. jolantag@umich.edu.
Program in Chemical Biology, University of Michigan, Ann Arbor, MI, USA. jolantag@umich.edu.
Publications dans "Histone méthyltransférases" :
2 publications dans cette catégorie
Affiliations :
Department of Pathology, University of Michigan, Ann Arbor, MI, USA. tomaszc@umich.edu.
Program in Chemical Biology, University of Michigan, Ann Arbor, MI, USA. tomaszc@umich.edu.
Department of Biophysics, University of Michigan, Ann Arbor, MI, USA. tomaszc@umich.edu.
Publications dans "Histone méthyltransférases" :
2 publications dans cette catégorie
Affiliations :
Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Publications dans "Histone méthyltransférases" :
2 publications dans cette catégorie
Affiliations :
Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Department of Medicine, Rhode Island Hospital and Alpert Medical School, Brown University, Providence, RI, United States.
Publications dans "Histone méthyltransférases" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory of Acupuncture and Medicine Research of Ministry of Education, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Publications dans "Histone méthyltransférases" :
2 publications dans cette catégorie
Affiliations :
Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Publications dans "Histone méthyltransférases" :
2 publications dans cette catégorie
Affiliations :
Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu 610041, China. zhubm64@hotmail.com.
Publications dans "Histone méthyltransférases" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology, Human Phenome Institute, School of Pharmacy, Fudan University, Shanghai, China.
State Key Laboratory of Quality Research in Chinese Medicine and School of Pharmacy, Macau University of Science and Technology, Taipa, China.
Publications dans "Histone méthyltransférases" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology, Human Phenome Institute, School of Pharmacy, Fudan University, Shanghai, China.
Publications dans "Histone méthyltransférases" :
2 publications dans cette catégorie
Affiliations :
Center for Neuroscience and Pain Research, Department of Anesthesiology and Perioperative Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas 77030; School of Physical Education, Jianghan University, Wuhan, Hubei 430056, China.
Publications dans "Histone méthyltransférases" :
2 publications dans cette catégorie
Affiliations :
Department of Biology, Georgia State University , Atlanta, GA, USA.
Publications dans "Histone méthyltransférases" :
2 publications dans cette catégorie
Affiliations :
Department of Biology, Georgia State University , Atlanta, GA, USA.
Publications dans "Histone méthyltransférases" :
2 publications dans cette catégorie
Affiliations :
Department of Biology, Georgia State University , Atlanta, GA, USA.
Key Laboratory on Cardiovascular, Cerebrovascular, and Metabolic Disorders, Hubei University of Science and Technology , Xianning, China.
Publications dans "Histone méthyltransférases" :
2 publications dans cette catégorie
Affiliations :
Department of Biology, Georgia State University , Atlanta, GA, USA.
Publications dans "Histone méthyltransférases" :
Hospitals represent complex organizations where a range of hospital workers, from physicians to administrators, encounter a deluge of information they must quickly process and act upon. New technologi...
This essay argues that we should treat science and risk communicators' choices about tactics, objectives, and goals as behaviors to advance both research and practice. Doing so allows for a discussion...
Serious illness communication in homecare about hospice and/or palliative care transitions is lacking due to clinical culture. The purpose of the current study was to understand communication openings...
The purpose of this study was to gain a comprehensive understanding of participation situations that are challenging for people with communication problems, to provide input for the further developmen...
A purposive sampling strategy was used to include a diverse group of people with communication problems. Diaries were used as a sensitizing exercise for inductive in-depth interviews. In these intervi...
Eighteen interviews yielded 44 different concepts. They were clustered in six themes, which capture the person, location, topic, mode, moment, and pace of communication. In total, 103 new items measur...
This study resulted in an overview of self-reported barriers in daily communicative participation experienced by people with communication problems. These communicative participation situations can be...
To explore how communication is perceived and care is negotiated amongst IA healthcare teams by drawing on the perspectives of each team member....
This analysis drew on data from an ongoing three-year study exploring team-based IA care. We interviewed 11 participants including two men with IA and their family care providers and healthcare provid...
Analysis revealed three themes regarding communication and care: (1) seeking/sharing information, (2) striving to coordinate unified care, and (3) providing patients a voice....
This study emphasizes the importance of understanding team dynamics beyond the dyad of patient and care provider. Negotiating power and decision-making in IA care is a dynamic process involving shifti...
To analyze the effect of communication training developed for adolescents on the youth's communication skills....
Forty-one young people participated in the study and were divided into two groups. Group I received intervention - communication training for five weeks; Group II - were guided on the importance of vo...
The analysis of questionnaires showed improvement in GI in two of the four skills assessed and no difference for GII. The video evaluations showed a significant difference between the groups in terms ...
This study points out that the communication training method applied to young people might improve communicative skills, providing some insights into their communication strengths and potential areas ...
Humans often communicate using body movements like winks, waves, and nods. However, it is unclear how we identify when someone's physical actions are communicative. Given people's propensity to interp...
The consequences of ineffective communication between patients and clinicians in the ED range from frustration to significant adverse events. Unfortunately, scenarios where we are unable to understand...
Many people with amyotrophic lateral sclerosis (PALS) experience speech changes, which may interfere with participation in communication situations. This study was designed to investigate the effects ...
Participants with amyotrophic lateral sclerosis completed an online questionnaire in which they identified their current communication methods, rated their speech function, and rated their communicati...
Communication aids appeared to support communicative participation for many participants with dysarthria. Across all levels of speech function, PALS who use aided communication reported better partici...
Aided communication can help PALS continue to participate in various communication situations as their speech function deteriorates. Variability in self-rated communicative participation, even for PAL...
https://doi.org/10.23641/asha.22782986....
Research has found that people with communication disabilities are three times more likely to encounter medical mishaps. Almost a third of patients with speech-language therapy (SLT) diagnoses have ot...
This study aims to describe the communication challenges and strategies employed by a group of final year Nursing, Medicine, Dietetics and Human Nutrition, Physiotherapy and Occupational Therapy stude...
A qualitative, phenomenological study design was used. Questionnaires were electronically distributed, and results were analysed thematically....
The most significant challenges whilst managing adults with communication disorders were patients' receptive and expressive language difficulties. Further challenges included lack of knowledge surroun...
This study revealed that there is a need to develop healthcare students' skills in managing adults with communication disorders. This is because of the challenges faced and inefficiency of the strateg...